Evidence map›Paper›PMID 23749387›Full record

ArticleCurrent urology reports2013

Update on the evaluation of repeated stone formers.

Adam O Kadlec, Thomas M Turk

Abstract read
PubMed Publisher
In one paragraph

Article in Current urology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. UPDATE - Canadian Urological Association guideline: Evaluation and medical management of kidney stones.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022
    Article
  3. Article
  4. Article
  5. CUA guideline on the evaluation and medical management of the kidney stone patient - 2016 update.Canadian Urological Association journal = Journal de l'Association des urologues du Canada
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Adam O KadlecDepartment of Urology, Loyola University Medical Center, 2160 S. First Ave, Bldg 54, Maywood, IL, 60153, USA, akadlec@lumc.edu.
Thomas M Turk

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Office management of stone disease is an important component of a urologist's practice. Evaluation should include analysis of stone composition, 24-hour urine studies, identification of modifiable risk factors, and targeted dietary, lifestyle, and/or medical therapy. A sizeable portion of investigated etiologies and risk factors for stone disease have centered on the complex interplay between obesity, diabetes, and other disease states that comprise the metabolic syndrome. Alternatives to traditional preventive therapy, such as probiotics and various fruit juices, are still being studied but may prove useful adjuncts to traditional preventive therapy, where the mainstays remain increased fluid intake, dietary modification, and pharmacologic therapy. Future studies on preventive therapy of urolithiasis are likely to focus on strategies to increase compliance, cost-effectiveness, and systems-based implementation.

Indexed as

Risk Reduction BehaviorAmbulatory CareDiet TherapyDiureticsHumansNephrolithiasisPotassium CitrateSecondary PreventionSodium Chloride Symporter InhibitorsUrolithiasisDiureticsPotassium CitrateSodium Chloride Symporter Inhibitors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.